Brought to you by 
Kite Pharma's IPO nets $118.6mm
03 Jul 2014
Executive Summary
Kite Pharma Inc. (autologous cell therapies for cancer) netted $118.6mm through its initial public offering of 7.5mm shares at $17. Shortly after the company filed in May, it set terms of 6mm shares at $12-14, and then raised the bar just a few weeks later, stating it hoped to sell 7.5mm shares at $15-16.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kite Pharma's IPO nets $118.6mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice